<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484415</url>
  </required_header>
  <id_info>
    <org_study_id>YHGT-CEV-R1</org_study_id>
    <nct_id>NCT04484415</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)</brief_title>
  <acronym>APRICITY</acronym>
  <official_title>A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asieris MediTech (Hong Kong) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Yahong Meditech Co., Ltd aka Asieris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to&#xD;
      evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade&#xD;
      squamous intraepithelial lesions (HSIL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of Cevira® compared to placebo in treatment of patients&#xD;
      with cervical histologic HSIL.A total of 384 subjects will be enrolled globally, among which,&#xD;
      300 subjects of them will be enrolled in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of responders at 6 months after first treatment</measure>
    <time_frame>6 months</time_frame>
    <description>A responder is defined as follows:&#xD;
Normal histology; or&#xD;
LSIL histology and clearance of baseline HPV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of HPV positive patients with clearance of baseline HPV at 6 months after first treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of HPV positive patients with clearance of baseline HPV at 6 months after first treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of HPV16 positive patients with clearance of HPV16 at 6 months after first treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of HPV16 positive patients with clearance of HPV16 at 6 months after first treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of HPV16 and/or HPV18 positive patients with clearance of baseline HPV at 6 months after first treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of HPV16 and/or HPV18 positive patients with clearance of baseline HPV at 6 months after first treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with histologic regression, defined as LSIL or normal histology, at 6 months after first treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of patients with histologic regression, defined as LSIL or normal histology, at 6 months after first treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 2/3</condition>
  <arm_group>
    <arm_group_label>Cevira® treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Cevira® treatment is an integrated combination of drug and device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo ointment contains only vehicle, and is similar in appearance and consistence as the Cevira® ointment. The placebo device is identical in appearance as the Cevira® device, but does not provide light.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cevira®</intervention_name>
    <description>The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.</description>
    <arm_group_label>Cevira® treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo device is identical in appearance as the Cevira® device, but does not provide light.</description>
    <arm_group_label>Placebo ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biopsy-confirmed HSIL histology determined by a panel of 3 pathologists from a central&#xD;
             laboratory in each region (China, US, and Europe);&#xD;
&#xD;
          2. Adequate colposcopy including:&#xD;
&#xD;
               1. visualization of entire cervical transformation zone including the squamocolumnar&#xD;
                  junction&#xD;
&#xD;
               2. visualization of entire lesion margin&#xD;
&#xD;
          3. Colposcopically visible lesion after biopsy, before treatment (Note: To ensure a&#xD;
             colposcopically visible lesion after biopsy, the lesion should cover approximately 15%&#xD;
             of the uterine cervix before biopsy)&#xD;
&#xD;
          4. Average sized uterine cervix suitable for application of the Cevira® device&#xD;
&#xD;
          5. Use of adequate birth control until completion of the 6 month assessment visit&#xD;
&#xD;
          6. Age 18 or older (Note: Patients aged 18-20 should not be actively recruited)&#xD;
&#xD;
          7. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Biopsy-confirmed HSIL (CIN3) histology with a total lesion area covering more than&#xD;
             half of the uterine cervix area&#xD;
&#xD;
          2. Invasive cervical cancer&#xD;
&#xD;
          3. Adenocarcinoma in situ, or other glandular intraepithelial lesions&#xD;
&#xD;
          4. Lesion(s) extending to the cervical canal (as clinically indicated and whether to&#xD;
             perform endocervical curettage [ECC] test at the discretion of the investigators)&#xD;
&#xD;
          5. Lesion(s) extending to the vaginal vault&#xD;
&#xD;
          6. Current severe pelvic inflammatory disease, severe cervicitis, or other severe&#xD;
             gynecological infection as per colposcopy and clinical examination&#xD;
&#xD;
          7. Vaginal bleeding at time of treatment at the discretion of the investigator&#xD;
&#xD;
          8. Pregnancy&#xD;
&#xD;
          9. Nursing&#xD;
&#xD;
         10. Childbirth or miscarriage within six weeks of enrolment&#xD;
&#xD;
         11. Patients who previously received surgical treatment, have incomplete cervical&#xD;
             structure and have recurrent HSIL; or patients who received other treatment after the&#xD;
             confirmed diagnosis of HSIL&#xD;
&#xD;
         12. History of toxic shock syndrome&#xD;
&#xD;
         13. Known or suspected porphyria&#xD;
&#xD;
         14. Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate&#xD;
             or aminolevulinic acid)&#xD;
&#xD;
         15. Known allergy to silicone&#xD;
&#xD;
         16. Use of heart pacemaker&#xD;
&#xD;
         17. Participation in other therapeutic clinical trials using investigational agents either&#xD;
             concurrently or within the last 30 days&#xD;
&#xD;
         18. Patients that in the investigator's opinion are not suitable for participation&#xD;
&#xD;
         19. Patient is the investigator or any sub-investigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff or relative thereof directly involved in the conduct of&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinghe Lang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Zhuang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asieris MediTech (Hong Kong) Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingming Zhang, MD</last_name>
    <phone>+8613816002336</phone>
    <email>mmzhang@asieris.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meng Liu, PhD</last_name>
    <phone>+8615901614217</phone>
    <email>mliu@asieris.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Chen, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

